Screener
Aclaris Therapeutics ACRS Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Net loss | $(41,329) | $(30,514) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 209 | 242 |
| Stock-based compensation expense | 5,870 | 6,598 |
| Revaluation of contingent consideration | 300 | 1,800 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, prepaid expenses and other assets | (477) | 7,155 |
| Accounts payable | 2,355 | 4,107 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's stock-based comp?
- Aclaris Therapeutics (ACRS) reported stock-based comp of $2.67M in Q2 2026.
- How has Aclaris Therapeutics's stock-based comp changed year-over-year?
- Aclaris Therapeutics's stock-based comp decreased by 12.8% year-over-year, from $3.06M to $2.67M.
- What is the long-term trend for Aclaris Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Aclaris Therapeutics's stock-based comp has grown at a -3.1% compound annual growth rate (CAGR), from $14.06M to $12.38M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Aclaris Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude